2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Non-Biological Therapies, Chemotherapy, Devices, Pharmacology, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research, AML, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

4226 TBI-based versus chemotherapy-based myeloablative conditioning for allogeneic HCT in adults with relapsed/refractory acute lymphoblastic leukemia: An EBMT ALWP study

Mingyang Wang, Thibeault Ferhat Berland, PhD2, Alexander Kulagin3, Hermann Einsele, MD, PhD4, Selami Koçak Toprak, MD5, Jakob Passweg, MD, MS6, Kerstin Schäfer-Eckart7, Renato Fanin8, Robert Zeiser, MD, PhD9, Matteo Parma10, Omur Gokmen Sevindik, MD11, Martin Kaufmann, MD12, Ibrahim Yakoub-Agha13, Antonio Pierini, MD, PhD14, Jan Maciej Zaucha, Prof, MD, PhD15, Wolfgang Bethge, MD16, Claude-Éric Bulabois17, Sebastian Giebel, MD18, Norbert Claude Gorin, MD, PhD19, Yigeng Cao II, MD, PhD20, Erlie Jiang, MD21, Jaime Sanz, MD, PhD22, Arnon Nagler I, MD23, Fabio Ciceri, MD24, Eolia Brissot, MD, PhD25
1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 EBMT Paris Office, Hôpital Saint-Antoine, AP-HP, Paris, France
3 RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russian Federation
4 Universitaetsklinikum Wuerzburg, Würzburg, Germany
5 Ankara University Faculty of Medicine, Ankara, Turkey
6 University Hospital | Basel, Basel, Switzerland
7 Klinikum Nuernberg, Nürnberg, Germany
8 Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy
9 University of Freiburg, Freiburg, Germany, University of Freiburg, Freiburg, Germany
10 Ospedale San Gerardo, Monza, Italy
11 Demiroglu Bilim University Istanbul Florence Nightingale Hospital, Istanbul, Turkey
12 Robert Bosch Krankenhaus, Stuttgart, Germany
13 CHU de Lille, Lille, France
14 University of Perugia, Perugia, Italy
15 University Clinical Centre in Gdansk, Gdansk, Poland
16 Universitaet Tuebingen, Tübingen, Germany
17 CHU Grenoble Alpes - Universite Grenoble Alpes, Grenoble, France
18 Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland
19 Department of Clinical Hematology and Cellular Therapy, Hôpital Saint-Antoine, AP-HP, Paris, France
20 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
21 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
22 Haematology Department, Hospital Universitari i Politècnic La Fe, Valencia Departament de Medicina, Universitat de Valencia, Valencia, Spain; CIBERONC, Instituto Carlos III, Madrid, Spain
23 Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel
24 Unit of Hematology and Stem Cell Transplantation, Ospedale San Raffaele, University Vita-Salute San Raffaele, Milan, Italy
25 EBMT Paris Office, Hôpital Saint-Antoine, AP-HP, Paris, France, Paris, France

Background

Relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) remains a major therapeutic challenge with scarce effective options and dismal long-term survival. Allogeneic hematopoietic cell transplantation (allo-HCT) offers a potentially curative approach; however, the optimal conditioning regimen for this high-risk population has not been established. The comparative efficacy of TBI- versus chemotherapy-based conditioning remains controversial. To address this, we leveraged the EBMT registry to compare the effectiveness of TBI-based and chemotherapy-based myeloablative conditioning in adults with R/R ALL undergoing allo-HCT.

Method

Consecutive adults (≥18 years) with R/R ALL undergoing a first allo-HCT after myeloablative conditioning between 2014 and 2023 were identified from the EBMT ALWP registry. Patients with prior autologous transplantation or cord blood transplantation were excluded. All donor types were included, with unrelated donors limited to 10/10 or 9/10 HLA-matched donors.

Results

A total of 413 adults with R/R ALL undergoing allo-HCT were included, including 238 (57.6%) patients with B-ALL and 175 (42.4%) with T-ALL. All patients received myeloablative conditioning, with 280 (67.8%) received TBI-based conditioning (TBI group) and 133 (32.2%) received chemotherapy-based conditioning (Chemo group). Donor age, donor sex, and donor/recipient CMV serostatus were comparable between groups. The Chemo group had more haploidentical donors than the TBI group (36.1% vs. 17.1%, P<0.001). The overall median follow-up was 3.1 years (95% CI, 2.8–4.4). In the TBI and Chemo groups, the 2-year overall survival (OS) was 31.0% versus 15.9%, leukemia-free survival (LFS) was 23.0% versus 9.5%, cumulative incidence of relapse (CIR) was 53.9% versus 66.7%, and non-relapse mortality (NRM) was 23.1% versus 23.8%, respectively. After adjusting for key variables, including patient age, donor type, and graft source, multivariable analyses showed that TBI-based conditioning was associated with a significantly lower risk of relapse (HR, 0.63; 95% CI, 0.47–0.86; P=0.004) without increasing NRM (HR, 0.82; 95% CI, 0.49–1.35; P=0.435). These benefits translated into improved OS (HR, 0.66; 95% CI, 0.51–0.87; P=0.003) and LFS (HR, 0.68; 95% CI, 0.52–0.88; P=0.004) among patients receiving TBI-based conditioning. Additionally, haploidentical donor transplantation was associated with reduced risk of relapse compared to matched unrelated donor transplantation (HR, 1.57; 95% CI, 1.02–2.39; P=0.039).

Conclusion

In adults with R/R ALL undergoing allo-HCT, TBI-based myeloablative conditioning was associated with a lower CIR and superior OS and LFS compared with chemotherapy-based myeloablative conditioning. These findings support TBI-based conditioning as the preferred myeloablative conditioning strategy for adults with R/R ALL undergoing allo-HCT.

Mingyang Wang: No relevant conflicts of interest to declare.